ERCC1 expression in patients with colorectal cancer: a pilot study

Abstract

Aim: Excision repair cross complementation group 1 (ERCC1) has a key role in enhanced DNA damage repair caused by oxaliplatin-based therapy and may lead to resistance of these platinum drugs in colorectal cancer (CRC) patients. Hence, the present preliminary study aimed to explore the role of ERCC1 C/T polymorphism at codon 118 as well as its immunoreactivity in patients with primary CRC. Methods: ERCC1 polymorphism was studied using PCR-RFLP and ERCC1 protein expression was examined by immunohistochemistry in 50 CRC patients. Results: ERCC1 codon 118 C/T polymorphism analysis reported the predominance of C/T (52%) genotype as compared to C/C (38%) and T/T (10%) genotypes. Furthermore, 72% of patients showed positive ERCC1 protein expression. Significant correlation was not observed between clinicopathological parameters and ERCC1 polymorphism, while ERCC1 protein expression significantly correlated only with tumor site (colon vs. rectum) (P = 0.046). Further, the present study failed to demonstrate the role of ERCC1 C118T polymorphism or protein expression as useful prognostic markers in CRC patients. Conclusion: ERCC1-positive protein expression may be a useful marker for rectal cancer patients. However, further evaluation in a larger set of CRC patients is required to better understand the role of ERCC1.

Keywords

Excision repair cross complementation group 1 / oxaliplatin / colorectal cancer / polymorphism / protein expression / PCR-RFLP / immunohistochemistry

References

[1] Heidelberger C,Danneberg P,Griesbach L,Schnitzer RJ,Scheiner J.Fluorinated pyrimidines, a new class of tumour-inhibitory compounds..Nature1957;179:663-6

[2] Zhang N,Xu SJ.5-Fluorouracil: mechanisms of resistance and reversal strategies..Molecules2008;13:1551-69

[3] de Gramont A,Seymour M,Hmissi A,Boni C,Cervantes A,Papamichael D,Louvet C,de Braud F,Morvan F.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer..J Clin Oncol2000;18:2938-47

[4] Chang PM,Chen PM,Lin TC,Jiang JK,Wang WS.ERCC1codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma..Cancer Sci2009;100:278-83

[5] Dabholkar M,Parker RJ,Bostick-Bruton F,Reed E.Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro..Environ Health Perspect1992;98:53-9 PMCID:PMC1519597

[6] De Silva IU,Clingen PH.Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells..Mol Cell Biol2000;20:7980-90 PMCID:PMC86408

[7] Raymond E,Woynarowski JM.Oxaliplatin: mechanism of action and antineoplastic activity..Semin Oncol1998;25:4-12

[8] Altaha R,Yu JJ.Excision repair cross complementing-group 1: gene expression and platinum resistance..Int J Mol Med2004;14:959-70

[9] Park DJ,Stoehlmacher J,Groshen S,Yun J,Mallik N.ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy..Clin Adv Hematol Oncol2003;1:162-6

[10] Kwon HC,Oh SY,Kim MC,Kim HJ.Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer..Ann Oncol2007;18:504-9

[11] Ferry KV,Johnson SW.Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF..Biochem Pharmacol2000;60:1305-13

[12] Zaanan A,Emile JF,Fléjou JF,Istanbullu M,Alhazmi K,Louvet C.ERCC1, XRCC1 and GSTP1 single nucleotide polymorphisms and survival of patients with colon cancer receiving oxaliplatin-based adjuvant chemotherapy..J Cancer2014;5:425-32 PMCID:PMC4026996

[13] Stoehlmacher J,Zhang W,Groshen S,Lenz HJ.A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer..Br J Cancer2004;91:344-54 PMCID:PMC2409815

[14] Wang AT,Cattell E,Hartley JM,Burgess-Brown NA,Enzlin JH,Gileadi O,McHugh PJ.Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair..Genes Dev2011;25:1859-70 PMCID:PMC3175721

[15] Li Y,Liu H,Tan D,Wei QY.ERCC1 and ERCC2 variants predict survival in gastric cancer patients..PLoS One2013;8:e71994

[16] Huang MY,Huang ML,Lin SR.Polymorphisms in XPD and ERCC1 associated with colorectal cancer outcome..Int J Mol Sci2013;14:4121-34 PMCID:PMC3588089

[17] Kim CY,An MS,Bae KB,Kim JH,Kang MS,Hong KH.ERCC1 as a predictive marker for FOLFOX chemotherapy in an adjuvant setting..Ann Coloproctol2015;31:92-7 PMCID:PMC4496459

[18] Liang R,Liu ZH,Yuan CL,Li YQ.Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer..Genet Mol Res2015;14:5804-11

[19] Yu JJ,Guo Y,Reed E.An ERCC1 splicing variant involving the 5′UTR of the mRNA may have a transcriptional modulatory function..Oncogene2001;20:7694-8

[20] Qi YJ,Yang YZ,Cai BJ,Ma Y,Ge RL.Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population..J Cancer Res Ther2013;9:410-5

[21] Takenaka T,Kiyohara C,Kouso H,Kometani T,Yoshino I.Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients..Lung Cancer2010;67:101-7

[22] Viguier J,Miquel C,Giraudeau B,Ducreux M,Praz F.ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer..Clin Cancer Res2005;11:6212-7

[23] Martinez-Balibrea E,Aranda E,Manzano JL,Gómez-Espa-a A,García T,Martínez-Cardús A,Guino E.Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer..Eur J Cancer2008;44:1229-37